




Impact of Valvular Heart Disease (VHD)in Adult Congenital Heart Disease (ACHD)

Francesca Graziani, MD, PhD
Policlinico Universitario A. Gemelli IRCCS, Rome
Ambulatorio Cardiologico Difetti Congeniti e Malattie Rare



ACHD-The Burden






ACHD-The Burden

- ✓ Increased knowledge [©] prenatale dx= early treatment
- ✓ Improvement of neonatal/pediatric care, including percutaneous and surgical treatments
- ✓ Improvement of medical therapies for the management of short- and long-term complications
- ✓ Prevention of arrhythmias/sudden cardiac death
- ✓ Dedicated clinical pathways and cardiac and non-cardiac specialists




ACHD Lifeexpectancy






ACHD Prognosis

Fondazione Policlinico Universitario Agostino Gemelli IRCCS Università Cattolica del Sacro Cuore



Heart Failure and Arrhythmias are the major determinant of mortality & hospitalization






ACHD Prognosis



Still significantly lower compared to age-matched population





			Pat	ient'	s age	(yea	ars)			
	20	25	30	35	40	45	50	55	60	Age difference:
ASD	25	26	32	38	42	47	52	57	61	>40
Valvar disease	29	31	36	40	45	49	54	59	63	30-40
VSD	28	30	36	40	44	49	53	59	63	20-30
Aortic Coarctation	32	33	38	43	47	52	56	62	66	10-20
AVSD	33	34	39	44	48	52	57	62	66	5-10
Marfan syndrome	37	38	42	46	50	54	59	64	68	2-5
Tetralogy of Fallot	37	38	42	47	50	54	60	65	69	<2
Ebstein anomaly	42	43	47	51	54	59	63	68	72	
Systemic RV	46	48	51	55	59	63	67	72	76	
Eisenmenger syndrome	57	58	62	65	69	73	77	81	84	
Complex CHD	58	59	63	67	70	74	78	82	85	
Fontan	64	65	68	72	75	78	82	86	91	



Università Cattolica del Sacro Cuore

ACHD-Corrected but not Cured

Clinical Cardiology: New Frontiers

Challenges Posed by Adults With Repaired Congenital Heart Disease

Joseph K. Perloff, MD; Carole A. Warnes, MD


TABLE 1. Residua After Reparative Surgery for Congenital **Heart Disease** Electrophysiological Valvular Ventricular Chamber morphology Chamber mass Chamber function Vascular Anatomic anomalies or defects Elevated systemic/pulmonary arterial pressure/resistance Noncardiovascular Development abnormalities Mental retardation Physical retardation (dwarfism) Somatic abnormalities (facial, musculoskeletal) Central nervous system abnormalities Focal neurological deficits Seizures Senses Visual abnormalities Auditory abnormalities Dental abnormalities

Medical disorders

TABLE 2. Seguelae After Reparative Surgery for Congenital **Heart Disease** Electrophysiological Atriotomy Intra-atrial repair Intraventricular repair Ventriculotomy Incision site Intracardiac repair Left ventricular or right ventricular outflow repair Left ventricular or right ventricular inflow repair Prosthetic materials **Patches** Valves Conduits Myocardial and endocardial Vascular Neurological



Factors contributing to the CV burden over their lifetime





Residual haemodynamic lesions

 The presence of significant residual haemodynamic lesions has been linked with worse outcomes

 The associated increase in mortality/morbidity may be acute or longer-term, and related to the residual lesion itself and its effect on the heart, and/or the requirement for further intervention



Examples of important residual lesion

- •Systemic AV valve regurgitation, particularly when affecting a morphological systemic right ventricle
- Pulmonary regurgitation in ToF
- •Significant residual shunts conferring ongoing volume overload
- Obstruction in any venous pathway
- •Obstruction and/or regurgitation anywhere in a Univentricular circulation
- Significant peripheral pulmonary stenosis
- •Residual straddling tissue post AVSD repair associated with LVOTO and AV valve regurgitation



ACHD-The Population

 Patients with prior repair and residual or new haemodynamic complications

 Patients with conditions not diagnosed or not considered severe enough to require surgery in childhood

Patients with prior palliation




-MV disease

VHD in ACHD patients

-AR/TR for VSD i.e

-MR for IHD



-MR/MS in AVSD

-post-valvulotomies




VHD in ACHD patients



/HD are the main cause of intervention/reintervention in ACHD

Diagnosis	No. (%)
Conotruncal anomaliesa	361 (36.7)
Ebstein/tricuspid valve disease	174 (17.7)
Pulmonary stenosis, RVOTO	92 (9.4)
Single ventricle	71 (7.2)
Atrioventricular septal defect	64 (6.5)
Subaortic stenosis, HCM	62 (6.3)
Coarctation, interrupted arch	23 (2.3)
Anomalous pulmonary vein	21 (2.1)
Marfan syndrome	14 (1.4)
Other	102 (10.4)
Total	984 (100)



Ionescu-Ittu et al., Ann Thorac Surg 2010

Holst et al., Ann Thorac Surg 2011



VHD in ACHD natients

Università Cattolica del Sacro Cuore

> Swiss Med Wkly. 2017 Oct 27;147:w14519. doi: 10.4414/smw.2017.14519. eCollection 2017.


Swiss Adult Congenital HEart disease Registry (SACHER) - rationale, design and first results


Daniel Tobler ¹, Markus Schwerzmann ², Judith Bouchardy ³, Reto Engel ⁴, Dominik Stambach ⁴ Christine Attenhofer Jost ⁵, Kerstin Wustmann ², Fabienne Schwitz ², Tobias Rutz ⁶, Harald Gabriel 7, Hans Peter Kuen 8, Christoph Auf der Maur 8, Angela Oxenius 9, Theresa Seeliger 9, Bruno Santos Lopes 9, Francesca Bonassin 9, Matthias Greutmann 9, On Behalf Of Sacher



Major adverse cardiovascular events in adult congenital heart disease: a population-based followup study from Taiwan

Yu-Sheng Lin, Pi-Hua Liu, Lung-Sheng Wu, Yu-Ming Chen, Chee-Jen Chang 1, Pao-Hsien Chu







VHD in ACHD patients

Does the presence of severe VHD (S-VHD) impact prognosis in ACHD patients?





Methods

- ✓ Single center observational clinical study
- ✓ Data have been prospectively collected within the framework of clinical pathway dedicated to ACHD patients at our Institution
- ✓ All patients evaluated in our ACHD outpatient clinic from Sep 2014 to Feb 2021 were screened

Exclusion criteria:

- Patent foramen ovale, mild CHD
- Cardiomyopathies
- Congenital arrhythmias without any structural abnormalities
- Fup <12 months



Methods

Clinical, imaging and operation details were obtained from the report of the *first* clinical outpatient evaluation:

- Clinical findings: age, gender, CHD diagnosis at birth, number of cardiac interventions performed before our first evaluation, age at cardiac intervention(s), presence of genetic syndrome, severity of the CHD lesion (, previous PM/ICD implantation, %Sat O₂, NYHA functional class, complained symptoms.
- o *ECG findings*: rhythm; PR interval; presence of right or left bundle branch block; QRS interval.
- o *Echocardiographic findings*: left ventricle ejection fraction (LVEF), right ventricle systolic function expressed by tricuspid annular plane systolic excursion (TAPSE), parameters of diastolic function (E/A; E/e', left atrium volume index, LAVi), right ventricle systolic pressure (RVSP), degree of valvular stenosis or regurgitation



Study Endpoints

Primary Endpoint Composite of cardiac death and/or cardiac hospitalization*

Cardiac hospitalization @ heart failure and/or arrhythmias

*excluded hospitalizations for planned or urgent procedures

Secondary Analysis

CV mortality and hospitalization under medical management

(censoring patients at the time of interventions)

We also recorded:

- major arrhythmias not requiring hospitalization
- ➤ the rate of cardiac interventions (percutaneous or surgical)



Definitions

Fondazione Policlinico Universitario Agostino Gemelli IRCCS Università Cattolica del Sacro Cuore

Table 4 Classification of congenital heart disease complexity

MILD:

- · Isolated congenital aortic valve disease and bicuspid aortic disease
- Isolated congenital mitral valve disease (except parachute valve, cleft leaflet)
- · Mild isolated pulmonary stenosis (infundibular, valvular, supravalvular)
- Isolated small ASD, VSD, or PDA
- Repaired secundum ASD, sinus venosus defect, VSD, or PDA without residuae or sequellae, such as chamber enlargement, ventricular dysfunction, or elevated PAP.

MODERATE: (Repaired or unrepaired where not specified; alphabetical order)

- Anomalous pulmonary venous connection (partial or total)
- · Anomalous coronary artery arising from the PA
- · Anomalous coronary artery arising from the opposite sinus
- · Aortic stenosis subvalvular or supravalvular
- · AVSD, partial or complete, including primum ASD (excluding pulmonary vascular disease)
- · ASD secundum, moderate or large unrepaired (excluding pulmonary vascular disease)
- · Coarctation of the aorta
- · Double chambered right ventricle
- · Ebstein anomaly
- · Marfan syndrome and related HTAD, Turner Syndrome
- PDA, moderate or large unrepaired (excluding pulmonary vascular disease)
- · Peripheral pulmonary stenosis
- · Pulmonary stenosis (infundibular, valvular, supravalvular), moderate or severe
- Sinus of Valsalva aneurysm/fistula
- · Sinus venosus defect
- · Tetralogy of Fallot repaired
- · Transposition of the great arteries after arterial switch operation
- · VSD with associated abnormalities (excluding pulmonary vascular disease) and/or moderate or greater shunt.


SEVERE: (Repaired or unrepaired where not specified; alphabetical order)


- · Any CHD (repaired or unrepaired) associated with pulmonary vascular disease (including Eisenmenger syndrome)
- Any cyanotic CHD (unoperated or palliated)
- Double-outlet ventricle
- · Fontan circulation
- Interrupted aortic arch
- · Pulmonary atresia (all forms)
- Transposition of the great arteries (except for patients with arterial switch operation)
- Univentricular heart (including double inlet left/right ventricle, tricuspid/mitral atresia, hypoplastic left heart syndrome, any other anatomic abnorms with a functionally single ventricle)
- Truncus arteriosus
- Other complex abnormalities of AV and ventriculoarterial connection (i.e. crisscross heart, heterotaxy syndromes, ventricular inversion).

ACHD ESC Guidelines 2022




Definitions







Study flow-chart






Baseline characteristics

Variables	Total (n=390)
Age (years)	34 (26-46)
Male (n,%)	189 (49)
Complexity of CHD (n,%)	
Mild	159 (41)
Moderate	191 (49)
Severe	40 (10)
Surgery in pediatric age (n,%)	
None	184 (47)
Corrective surgery	179 (46)
Palliative surgery	27 (7)
Previous implantation of PM/ICD (n,%)	30 (8)
Af/Afib (n,%)	22 (6)
HR (bpm)	73 ± 13
QRS (ms)	105 (94-126)
Sat O ₂ (%)	98 (97-98)
NYHA class II-IV	146 (37)
LVEF (%)	61 ± 7
LAVi (ml/m2)	31 (24-43)
E/E' ratio	7 (5-8)
S-VHD (n,%)	101 (26)
TAPSE (mm)	22 ± 5
RVSP (mmHg)	30 (25-40)
RVSP>45 mmHg (n,%)	29 (7)



Baseline characteristics


Distribution of Severe CHD





S-VHD distribution

Fondazione Policlinico Universitario Agostino Gemelli IRCCS Università Cattolica del Sacro Cuore





	Variables	S-VHD (n=101)	NS-VHD (n=289)	p-value
\Longrightarrow	Age (years)	40 (30-54)	33 (24-44)	<0.001
	Male (n,%)	49 (49)	140 (48)	0.990
\Longrightarrow	Complexity of CHD (n,%)			
	Mild	23 (23)	136 (47)	<0.001
	Moderate	63 (62)	128 (44)	
	Severe	15 (15)	25 (9)	
	Surgery in pediatric age (n,%)			
	None	37 (37)	147 (51)	0.0014
	Corrective surgery	53 (53)	127 (44)	
	Palliative surgery	11 (10)	15 (5)	
	Previous implantation of PM/ICD (n,%)	10 (10)	20 (7)	0.343
\Longrightarrow	Af/Afib (n,%)	15 (15)	7 (3)	<0.001
	HR (bpm)	73 ± 15	72 ± 12	0.49
	QRS (ms)	117 (101-149)	103 (93-119)	<0.001
	Sat O ₂ (%)	97 (95-98)	98 (97-99)	<0.001
	NYHA class II-IV (n,%)	57 (57)	89 (31)	<0.001
	LVEF (%)	60 ± 6	62 ± 7	0.027
	LAVi (ml/m2)	41 (27-61)	29 (23-40)	<0.001
	E/E' ratio	7 (5-10)	6 (5-8)	0.344
	TAPSE (mm)	20 ± 6	22 ± 5	0.006
	RVSP (mmHg)	40 (30-55)	30 (25-35)	<0.001
	RVSP>45 mmHg (n,%)	17 (17)	12 (4)	<0.001



To further confirm the prognostic value of S-VHD on the clinical evolution, the occurrence of cardiac mortality or cardiac hospitalization without cardiac operations was examined.

After a median follow-up of 23 months (range: 9-44), 68 events occurred. At univariable Cox regression analysis, S-VHD was significantly associated with outcomes in patients medically treated (HR: 3.473 €2.144-5.627 ; p<0.001). The adjustment for significant clinical and echocardiographic variables (age, severe CHD, Af/Afib, NYHA class ≥II, LVEF and increased RVSP) did not affect the powerful association of S-VHD with the occurrence of the composite endpoint under medical management (HR: 1.920 €1.093-3.373 ; p=0.023).



Over a median follow-up time of 26 months (range:12-48) the *primary endpoint* occurred in a total of 76 patients (19.5%)


A **cardiac intervention** was performed in 78 patients

Patients with S-VHD

- more frequently *percutaneous or surgical intervention* (41.6% vs 12.5%, p<0.001)
- more *arrhythmias* occurred in patients with S-VHD (32.7% vs 15.2%, p<0.001)



Median FUP: 26 months (IQR:12-48): Primary Endpoint 6 76 pts






Università Cattolica del Sacro Cuore

Results

	Univariable ana	alysis	Multivariable analysis			
Variables	OR (95% CI)	p-value	OR (95% CI)	p-value		
Age (years)	1.037 (1.020-1.054)	<0.001	1.022 (1.002-1.041)	0.029		
Male	0.981 (0.623-1.546)	0.935				
Severe CHD	3.483 (2.086-5.816)	<0.001	1.332 (0.663-2.673)	0.421		
Surgery in pediatric age	1.376 (0.865-2.186)	0.177				
Af/Afib	6.444 (3.224-12.877)	<0.001	3.214 (1.408-7.333)	0.006		
HR (bpm)	1.011 (0.994-1.029)	0.209				
QRS duration (ms)	1.007 (0.999-1.014)	0.075				
Sat O ₂ (%)	0.934 (0.914-0.955)	<0.001	0.956 (0.926-0.986)	0.005		
NYHA class II-IV	4.224 (2.613-6.827)	<0.001	2.246 (1.270-3.974)	0.005		
Surgical or percutaneous intervention (time-dependent)	1.503 (0.745-3.031)	0.255				
LVEF (%)	0.922 (0.896-0.948)	<0.001	0.952 (0.918-0.987)	0.008		
LAVi (ml/m2)	1.000 (0.998-1.003)	0.657				
E/E' ratio	1.049 (0.932-1.181)	0.426				
S-VHD	3.258 (2.073-5.121)	<0.001	1.925 (1.133-3.271)	0.015		
TAPSE (mm)	0.901 (0.856-0.949)	<0.001				
RVSP >45 mmHg	1.029 (1.017-1.040)	<0.001	2.023 (0.955-4.286)	0.066		

CV mortality or hospitalization without cardiac operations: 1.920 ■1.093-3.373 ; p=0.023





^{*} Clinical model: Age, severe CHD, Af/Afib, Sat O_2 (%), NYHA class $\geq II$




Total number of events in the overall population and two subgroups

Outcome	Total population	S-VHD	NS-VHD	p-value
	(n=390)	(n=101)	(n=289)	
Cardiac hospitalization (n,%)	74 (19.0)	36 (35.6)	38 (13.1)	<0.001
Cardiac death (n,%)	8 (2.1)	6 (6.1)	2 (0.7)	0.001




Association between each subtype of S-VHD and the primary endpoint







ccTGA, systemic RV systolic dysfunction







Examples









S/P AVSD repair, no S-VHD MACE-

S/P AVSD repair, S-VHD MACE+

Fontan, normal EF, no S-VHD MACE- Fontan, normal EF, S-VHD MACE+



Conclusions

✓ The occurrence of **severe** VHD in ACHD patients is a significant independent predictor of CV hospitalization or death

✓ The prognostic value of severe valve dysfunction is incremental above other established prognostic markers and consistent independently from CHD severity




Insights

- Mean age 34 [©] >50% moderate or severe VHD
- Difficult to dissect the individual burden of each VHD subtype



DISEASE 12345



WIDE VARIETY OF DISEASE







Fondazione Policlinico Universitario Agostino Gemelli IRCCS Università Cattolica del Sacro Cuore

VHD in ACHD patients

The Individual
Patient Can Fit
Multiple Different
Classification






 $\begin{array}{ccc} & BAV \longrightarrow & \textit{CoA} \\ & & Ebstein \longrightarrow & \textit{ASD, PFO, WPW} \\ & & & & Shone \ \textit{Complex} \end{array}$




Insights-Echocardiography


First-line investigation





Evolution of standard echocardiography





Basilveical idefaculties

- •Abnoposition © systemic RV and UVH
 - •Venous return
- •Misleading Doppler gradients © RVOTO,

CoA, Stemostes in steries ria and ventricles

•Venous return and great arteries difficult to imageigin of the great arteries





TAKE HOME MESSAGES


- ✓ ACHD patients retain a life-long risk for CV complications (never cured)
- ✓ Main causes of death: heart failure/arrythmias
- ✓ VHD are the main cause of intervention/reintervention in adulthood
- ✓ S-VHD is independently associated to the risk of CV death and hospitalization
- ✓ Strict follow-up, dedicated multidisciplinary care team





Residual haemodynamic lesions- Case


Fondazione Policlinico Universitario Agostino Gemelli IRCCS Università Cattolica del Sacro Cuore





Fondazione Policlinico Universitario Agostino Gemelli IRCCS Università Cattolica del Sacro Cuore

Residual haemodynamic lesions-Case





Fondazione Policlinico Universitario Agostino Gemelli IRCCS Università Cattolica del Sacro Cuore

Grazie